MAPT and early-onset autosomal dominant Alzheimer disease: Moreover, in cohort−1, plasma BD-tau was associated with baseline performance on both the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) verbal memory recall and the Trail Making Test-B (TMT-B, Fig. 3A); b = −0.16, p < 0.001 and b = 0.12, p < 0.01 respectively), as well as the longitudinal worsening in performance on both tests over up to 8 years later (b = −0.05, p < 0.05; b = 0.04, p < 0.001 respectively, Supplementary Table 3).